

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

· · · · · · · · · · · · · · · · · · ·) Art Unit: 1614) Examiner:
Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450	
February 26, 2004	
TRANSMITTAL LETTER FOR INFORMA	ATION DISCLOSURE STATEMENT
Sir:	
Transmitted herewith concerning the subject applicatement (Form 1449A/B) under 37 C.F.R. §§1.5 patents and references, as more specifically described.	6 and 1.97, with copies of all non-US
1.97(b). This Statement is being filed date of a national application other than a continue §1.53 (d); ii) within three (3) months of the date of 37 C.F.R. §1.491 in an international application; ii on the merits; or iv) before the mailing of a first O continued examination under 37 C.F.R. §1.114.	f entry of the national stage as set forth in ii) before the mailing of a first Office action
1.97(c). This Statement is being file C.F.R. §1.97(b), but before the mailing date of: i) notice of allowance under 37 C.F.R. §1.311, or iii) prosecution in the application. This Statement is being file.) an action that otherwise closes
A statement as specified in 37 C.F	.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17	7(p).
The Commissioner is hereb \$180.00 fee set forth in 37 C.F.R. §	y authorized to charge payment of the \$1.17(p) to Deposit Account No.

] §1.97(c stateme §1.17(j	ent as sp	This Statement is being filed after the period specified in 37 C.F.R. or before payment of the issue fee. This Statement is accompanied by a ecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e).	
	stateme	Each item of information contained in the instant information disclosure nt was first cited in any communication from a foreign patent office in a part foreign application not more than three (3) months prior to the filing of ant information disclosure statement; or
	stateme foreign making informa C.F.R.	No item of information contained in the instant information disclosure ent was cited in a communication from a foreign patent office in a counterpart application, and, to the knowledge of the person signing this certification after a reasonable inquiry, no item of information contained in the instant ation disclosure statement was known to any individual designated in 37 §1.56(c) more than three (3) months prior to the filing of the instant ation disclosure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
in sec	erpart ap	d). Each item of information contained in the accompanying information ement was cited in a communication from a foreign patent office in a plication, which communication was not received by any individual designated 5(c) more than thirty (30) days prior to the filing of the accompanying sclosure statement.
fees ro	equired ι	ommissioner is hereby authorized to charge payment of any additional filing under 37 C.F.R. §1.16 and any patent application processing fees under 37 or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Michael P. Morris

Attorney for Applicant(s)

Michael Monis

Reg. No. 27,928

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-5285 Date: February 26, 2004 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on February 26, 2004.

Michael P. Monis

Michael P. Morris, Reg. No. 34,513

PTO/SB/08a (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Complete if Known Application Number 10/719,125 Filing Date 11/21/2003 First Named Inventor Franz BIRKE Art Unit 1614 **Examiner Name**

(Use as many sheets as necessary) Sheet

Attorney Docket Number 1/1421 1

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 5,731,332	03/24/1998	Anderskewitz, R. et al	
***************************************		^{US-} 6,172,096 B1	01/09/2001	Gregory, S. A. et al	
		^{US-} 6,197,753 B1	03/06/2001	Anderskewitz, R. et al	
		^{US-} 6,197,824 B1	03/06/2001	Schromm, K. et al	
		^{US-} 6,265,612 B1	07/24/2001	Schromm, K. et al	
		^{US-} 6,291,531 B1	09/18/2001	Anderskewitz, R. et al	
		^{US-} 6,417,382 B2	07/09/2002	Brandenburg, J. et al	
		^{US-} 6,576,669 B2	06/10/2003	Anderskewitz, R. et al	
		^{US-} 2003/0119901 A1	06/26/2003	Becker, R. et al	
	İ	US-			
		US-			-

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ 'Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	76		
		WO 03/007922						
	1				,			
								
	1							

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~							
	Substitute for	form 1449B/PTO				Complete if Known	
					Application Number	10/719,125	
	INFO	RMATION DI	SCLO	SURE	Filing Date	11/21/2003	
	STAT	EMENT BY A	APPLI	CANT	First Named Inventor	Franz BIRKE	***
					Art Unit	1614	
		(Use as many sheets as	necessary)		Examiner Name		
	Sheet	2	of	2	Attorney Docket Number	1/1421	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
		CARTER, ET AL; "5-Lipoxygenase inhibitory activity of zileuton"; J. Pharmacol. Exp. Ther., Vol. 256, (1991), pgs 929-937.				
•••••			ļ			
•••••			ļ			
•••••			ļ			
······································			<u> </u>			
			ļ			
Examiner		Date				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Signature

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language I translation is attached. This collection of information is required to by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.